John M. Leonard, President and CEO of Intellia Therapeutics, Inc. (NASDAQ:NTLA), filed a Form 4 on November 3, 2026, disclosing the sale of 9,000 shares of common stock on November 2, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 9,000 shares of Intellia Therapeutics common stock were disposed of on November 2, 2026.
  • Weighted average price: The reported sale price was $11.99 per share, representing a weighted average across multiple transactions ranging from $11.65 to $12.60, inclusive.
  • 10b5-1 plan: According to the filing, the sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by Leonard on May 21, 2026.
  • Direct beneficial ownership after transaction: Leonard directly holds 1,138,064 shares of common stock following the reported sale.
  • Indirect holdings: An additional 58,415 shares are held indirectly by the John M. Leonard 2015 Irrevocable Trust.
  • Dual role: The filing identifies Leonard as both a Director and an Officer, serving as President and CEO of Intellia Therapeutics.

CEO Share Sale Details and Ownership Position at Intellia Therapeutics

According to the Form 4 filed with the U.S. Securities and Exchange Commission, John M. Leonard, who serves as both a Director and President and CEO of Intellia Therapeutics, Inc., sold 9,000 shares of the company's common stock on November 2, 2026. Intellia Therapeutics is a genome editing company focused on developing in vivo and ex vivo therapeutics using CRISPR/Cas9 technology. The filing identifies the issuer as trading on NASDAQ under the symbol NTLA.

The filing states that the sales "occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026." The reported price of $11.99 per share is described as a weighted average, with individual transactions priced between $11.65 and $12.60, inclusive. The filing notes that full per-price detail is available upon request from the Commission staff, the company, or a security holder. Following the transaction, Leonard's direct beneficial ownership stands at 1,138,064 shares, with an additional 58,415 shares held indirectly through the John M. Leonard 2015 Irrevocable Trust.

The Form 4 was signed by James Basta as attorney-in-fact on behalf of Leonard and filed on November 3, 2026, one day after the transaction date. The checkbox on the form indicates the transaction was made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c), as described in Instruction 10 of the form.

What Was Disclosed

The filing reports a single open-market sale of 9,000 Intellia Therapeutics common shares by President and CEO John M. Leonard on November 2, 2026, executed under a 10b5-1 plan adopted May 21, 2026, at a weighted average price of $11.99 per share.